愿景控股公司从一家中国公司获得糖尿病和免疫性疾病的干细胞疗法的全球权利。 Visionary Holdings secures global rights to a stem cell therapy for diabetes and immune diseases from a Chinese firm.

视觉控股公司 (GV) 于2025年10月13日宣布,其亚洲子公司已获得江苏再造医药公司的干细胞技术全球许可. Visionary Holdings (GV) announced on October 13, 2025, that its Asia subsidiary has obtained a global license for a stem cell technology from Jiangsu Yike Regenerative Medicine. 该平台以糖尿病、免疫疾病和新陈代谢紊乱为对象,早期数据显示,有可能恢复胰腺功能,实现1型糖尿病和2型糖尿病的长期缓解或治愈。 The platform targets diabetes, immune diseases, and metabolic disorders, with early data showing potential to restore pancreatic function and achieve long-term remission or cures for both Type 1 and Type 2 diabetes. 该协议授予全球价值链在全世界发展和商业化该技术的权利,Yike则获得许可证和研发收入,并不断提供科学支持。 The deal grants GV worldwide rights to develop and commercialize the technology, while Yike receives licensing and R&D income and provides ongoing scientific support. 合作的目的是推进基于细胞的治疗,解决全球糖尿病市场超过1 500亿美元的问题。 The collaboration aims to advance cell-based therapies and addresses a global diabetes market exceeding $150 billion.